Skip to main content
Quest Diagnostics

Detection of Treatment-Resistant ESR1 Mutations by Ultra-sensitive SuperRCA® Technology

SABCS 2025

San Antonio Breast Cancer Symposium

San Antonio, TX, Dec 9-12, 2025

Poster presentation: Detection of Treatment-Resistant ESR1 Mutations by Ultra-sensitive SuperRCA® Technology

Authors: Nguyen D, Chen L, Radic V, Ma C, Racke F

Medical Specialty: Oncology

Related content

Audio Podcast
Optimize Oncology Care with Clinical Pathways
Publication
The Symptom Burden of Women With a Known Risk of Breast Cancer Receiving Risk Reducing Medication
Test FAQ
Solid Tumor Core Panel
Publication
A Genomics-Driven Artificial Intelligence-Based Model Classifies Breast Invasive Lobular Carcinoma and Discovers CDH1 Inactivating Mechanisms

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2025 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.